Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SNDX Syndax Pharmaceuticals, Inc.

已收盘 08-16 16:00:00 EDT

19.93

-0.03

-0.15%

盘后20.20

+0.27+1.35%

19:00 EDT

最高20.15	最低19.79	成交量63.23万
今开20.03	昨收19.96	日振幅1.83%
总市值16.96亿	流通市值16.89亿	总股本8,510万
成交额1,262万	换手率0.75%	流通股本8,476万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals, Inc. ","latestPrice":19.93,"timestamp":1723838400000,"preClose":19.96,"halted":0,"volume":632343,"hourTrading":{"tag":"盘后","latestPrice":20.2,"preClose":19.93,"latestTime":"19:00 EDT","volume":57034,"amount":1136834.28,"timestamp":1723849204651},"delay":0,"floatShares":84756780,"shares":85096358,"eps":-3.380417,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.03,"latestTime":"08-16 16:00:00 EDT","open":20.03,"high":20.15,"low":19.785,"amount":12622536.926505001,"amplitude":0.018287,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.380417,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1724054400000},"adr":0,"listingDate":1456981200000,"adjPreClose":19.96,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":20.03,"preClose":19.96,"latestTime":"09:29 EDT","volume":871,"amount":17442.500543,"timestamp":1723814999999},"postHourTrading":{"tag":"盘后","latestPrice":20.2,"preClose":19.93,"latestTime":"19:00 EDT","volume":57034,"amount":1136834.28,"timestamp":1723849204651},"volumeRatio":0.611863,"impliedVol":0.6822,"impliedVolPercentile":0.3452},"requestUrl":"/m/hq/s/SNDX/wiki","defaultTab":"wiki","newsList":[{"id":"2459403760","title":"BUZZ-美国食品和药物管理局批准 Syndax 治疗慢性移植物抗宿主病，该公司业绩上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2459403760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459403760?lang=zh_cn&edition=full","pubTime":"2024-08-16 01:37","pubTimestamp":1723743463,"startTime":"0","endTime":"0","summary":"    8月15日 - ** Syndax制药公司  的股票在下午的交易中上涨了4%，达到20.37美元。** 美国食品和药物管理局周三晚些时候批准了  Syndax和合作伙伴Incyte公司  的药物Niktimvo，用于治疗慢性移植物抗宿主疾病患者(GvHD。** Niktimvo获准用于先前至少两种疗法失败的成人和儿童患者。** 该批准为Niktimvo在三线治疗市场与赛诺菲  的Rezurock竞争提供了 \"差异化机制\"--BTIG分析师。** Syndax和Incyte计划在2024年第四季度推出Niktimvo，并在上市时公布定价 ** 包括盘中涨幅在内，该股今年累计下跌约 4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","INCY","BK4532","BK4550","BK4585","BK4139","BUZZ","BK4588"],"gpt_icon":0},{"id":"2459425477","title":"Syndax Pharmaceuticals, Inc.盘中异动 大幅拉升5.06%报20.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459425477","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459425477?lang=zh_cn&edition=full","pubTime":"2024-08-16 00:14","pubTimestamp":1723738489,"startTime":"0","endTime":"0","summary":"北京时间2024年08月16日00时14分，Syndax Pharmaceuticals, Inc.股票出现异动，股价快速拉升5.06%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.36%。其相关个股中，Cingulate Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Nutriband Inc C/Wts 涨幅较大，Cingulate Inc.、Scisparc Ltd.、Altamira Therapeutics Ltd.较为活跃，换手率分别为7178.21%、2216.80%、602.35%，振幅较大的相关个股有Nutriband Inc C/Wts 、Seastar Medical Holding Corp C/Wts 28/10/2027 、Nls Pharmaceutics Ltd C/Wts 02/02/2026，振幅分别为115.79%、103.98%、103.00%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816001449a1d47575&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816001449a1d47575&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2458515730","title":"Syndax Pharmaceuticals, Inc.2024财年第二财季实现净利润-68.06百万美元，同比减少52.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458515730","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458515730?lang=zh_cn&edition=full","pubTime":"2024-08-10 00:22","pubTimestamp":1723220520,"startTime":"0","endTime":"0","summary":"8月10日，Syndax Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第二财季净利润为-68.06百万美元，同比减少52.53%；其中营业收入为3.50百万美元，每股基本收益为-0.80美元。机构评级：截至2024年8月10日，当前有13家机构对Syndax Pharmaceuticals, Inc.目标价做出预测，其中目标均价为34.31美元，其中最低目标价为23.00美元，最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240810002204958c4db8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240810002204958c4db8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX"],"gpt_icon":0},{"id":"2457775267","title":"Syndax Pharmaceuticals, Inc.盘中异动 急速下挫5.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457775267","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457775267?lang=zh_cn&edition=full","pubTime":"2024-08-05 21:32","pubTimestamp":1722864769,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日21时32分，Syndax Pharmaceuticals, Inc.股票出现波动，股价快速下跌5.63%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.36%。其相关个股中，Zevra Therapeutics, Inc.、Alzamend Neuro, Inc.、Cns Pharmaceuticals, Inc.涨幅较大，Cns Pharmaceuticals, Inc.、Dermata Therapeutics, Inc.、Senti Biosciences, Inc.较为活跃，换手率分别为981.75%、35.48%、13.54%，振幅较大的相关个股有Vor Biopharma Inc.、Cue Biopharma, Inc.、Compass Therapeutics, Inc.，振幅分别为13.04%、12.33%、12.19%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805213249957f2e71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240805213249957f2e71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2455915663","title":"Syndax Pharmaceuticals Inc    预计每股亏损 91 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455915663","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455915663?lang=zh_cn&edition=full","pubTime":"2024-07-31 07:22","pubTimestamp":1722381741,"startTime":"0","endTime":"0","summary":"   * Syndax Pharmaceuticals Inc    将于8月1日公布截至2024年6月30日的财报，预计季度营收将保持不变。*    * LSEG分析师对Syndax Pharmaceuticals Inc的平均预期是每股亏损91美分。* 华尔街对 Syndax Pharmaceuticals Inc 的 12 个月目标价中位数为 35.00 美元，高于其上次收盘价 22.41 美元。7月30日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2455866513","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘大幅下跌14.25%报21.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2455866513","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455866513?lang=zh_cn&edition=full","pubTime":"2024-07-29 21:31","pubTimestamp":1722259914,"startTime":"0","endTime":"0","summary":"北京时间2024年07月29日21时31分，Syndax Pharmaceuticals, Inc.股票出现波动，股价快速跳水14.25%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Lipella Pharmaceuticals Inc.、Nls Pharmaceutics Ltd.、Anew Medical Inc C/Wts 21/06/2029 涨幅较大，Lipella Pharmaceuticals Inc.、Palisade Bio, Inc.、Nls Pharmaceutics Ltd.较为活跃，换手率分别为1257.40%、135.75%、115.12%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Nls Pharmaceutics Ltd.、Jasper Therapeutics Inc C/Wts 24/09/2026 ，振幅分别为56.92%、28.26%、25.18%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407292131549566fce4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407292131549566fce4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2454872307","title":"Syndax Pharmaceuticals, Inc.盘中异动 急速拉升5.00%报24.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454872307","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454872307?lang=zh_cn&edition=full","pubTime":"2024-07-25 22:19","pubTimestamp":1721917174,"startTime":"0","endTime":"0","summary":"北京时间2024年07月25日22时19分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速拉升5.00%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.89%。其相关个股中，Psyence Biomedical Ltd.、Salarius Pharmaceuticals, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Salarius Pharmaceuticals, Inc.、Psyence Biomedical Ltd.、Azitra Inc较为活跃，换手率分别为2088.64%、415.87%、164.74%，振幅较大的相关个股有Psyence Biomedical Ltd.、Salarius Pharmaceuticals, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为114.90%、98.60%、82.05%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725221935af941fe2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725221935af941fe2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2452216202","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452216202","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452216202?lang=zh_cn&edition=full","pubTime":"2024-07-18 00:48","pubTimestamp":1721234905,"startTime":"0","endTime":"0","summary":"北京时间2024年07月18日00时48分，Syndax Pharmaceuticals, Inc.股票出现波动，股价大幅跳水5.00%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为2.21%。其相关个股中，Aptevo Therapeutics Inc.、Geovax Labs Inc C/Wts 29/09/2025、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Aptevo Therapeutics Inc.、Aditxt, Inc.、Longeveron Inc.较为活跃，换手率分别为3323.58%、1382.05%、294.53%，振幅较大的相关个股有Aptevo Therapeutics Inc.、Aditxt, Inc.、4D Molecular Therapeutics, Inc.，振幅分别为76.39%、46.25%、45.71%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180048259681db94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180048259681db94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2450074235","title":"Syndax Pharmaceuticals, Inc.盘中异动 股价大涨5.02%报22.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450074235","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450074235?lang=zh_cn&edition=full","pubTime":"2024-07-10 03:22","pubTimestamp":1720552938,"startTime":"0","endTime":"0","summary":"北京时间2024年07月10日03时22分，Syndax Pharmaceuticals, Inc.股票出现波动，股价大幅上涨5.02%。截至发稿，该股报22.19美元/股，成交量49.6093万股，换手率0.58%，振幅6.34%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.83%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710032218941f57e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240710032218941f57e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2448949937","title":"Syndax Pharmaceuticals, Inc.盘中异动 下午盘大幅拉升5.11%报21.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448949937","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448949937?lang=zh_cn&edition=full","pubTime":"2024-07-02 02:38","pubTimestamp":1719859139,"startTime":"0","endTime":"0","summary":"北京时间2024年07月02日02时38分，Syndax Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.11%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.84%。其相关个股中，Senti Biosciences, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Seastar Medical Holding Corporation涨幅较大，Senti Biosciences, Inc.、Geovax Labs, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为765.20%、202.08%、122.99%，振幅较大的相关个股有Senti Biosciences, Inc.、Cingulate Inc.、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ，振幅分别为101.49%、82.81%、56.57%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702023859af900bc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702023859af900bc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2446025355","title":"Syndax Pharmaceuticals(SNDX.US)获杰富瑞投资银行首次覆盖，给予买入评级, 目标价37.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446025355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446025355?lang=zh_cn&edition=full","pubTime":"2024-06-28 20:48","pubTimestamp":1719578929,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2445798214","title":"Syndax Pharmaceuticals, Inc.盘中异动 下午盘快速拉升5.03%报20.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445798214","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445798214?lang=zh_cn&edition=full","pubTime":"2024-06-22 01:36","pubTimestamp":1718991366,"startTime":"0","endTime":"0","summary":"北京时间2024年06月22日01时36分，Syndax Pharmaceuticals, Inc.股票出现异动，股价急速拉升5.03%。截至发稿，该股报20.24美元/股，成交量35.8686万股，换手率0.42%，振幅4.31%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.18%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240622013607941f02b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240622013607941f02b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2443562875","title":"Syndax Pharmaceuticals, Inc.盘中异动 快速上涨5.02%报20.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2443562875","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443562875?lang=zh_cn&edition=full","pubTime":"2024-06-13 00:32","pubTimestamp":1718209940,"startTime":"0","endTime":"0","summary":"北京时间2024年06月13日00时32分，Syndax Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.02%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。其相关个股中，Longeveron Inc.、Cingulate Inc C/Wts 10/12/2026 、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Longeveron Inc.、Tonix Pharmaceuticals Holding Corp.、Tracon Pharmaceuticals, Inc.较为活跃，换手率分别为413.09%、113.30%、34.63%，振幅较大的相关个股有Longeveron Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Nls Pharmaceutics Ltd C/Wts 02/02/2026，振幅分别为113.52%、85.53%、76.92%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240613003221af8d34eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240613003221af8d34eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2441743808","title":"HC Wainwright &amp; Co.：重申Syndax Pharmaceuticals(SNDX.US)评级由买入调整至买入评级, 目标价由41.","url":"https://stock-news.laohu8.com/highlight/detail?id=2441743808","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441743808?lang=zh_cn&edition=full","pubTime":"2024-06-06 22:20","pubTimestamp":1717683641,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2441748707","title":"HC Wainwright &amp; Co.：重申Syndax Pharmaceuticals(SNDX.US)评级，由买入调整至买入评级, 目标价由41.","url":"https://stock-news.laohu8.com/highlight/detail?id=2441748707","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441748707?lang=zh_cn&edition=full","pubTime":"2024-06-06 22:12","pubTimestamp":1717683123,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2440484496","title":"Syndax Pharmaceuticals, Inc.盘中异动 早盘急速上涨5.14%报20.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2440484496","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440484496?lang=zh_cn&edition=full","pubTime":"2024-06-03 22:01","pubTimestamp":1717423303,"startTime":"0","endTime":"0","summary":"北京时间2024年06月03日22时01分，Syndax Pharmaceuticals, Inc.股票出现异动，股价大幅拉升5.14%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.05%。其相关个股中，Surrozen Inc C/Wts 01/08/2031 、Cingulate Inc C/Wts 10/12/2026 、Biocardia Inc C/Wts 06/08/2024涨幅较大，Bio-Path Holdings, Inc.、Scorpius Holdings, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃，换手率分别为2276.86%、70.14%、30.10%，振幅较大的相关个股有Bio-Path Holdings, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 、Scorpius Holdings, Inc.，振幅分别为57.28%、44.05%、27.03%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240603220143af8ba942&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240603220143af8ba942&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2436945214","title":"Syndax Pharmaceuticals, Inc.2024财年第一财季实现净利润-72.40百万美元，同比减少76.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2436945214","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2436945214?lang=zh_cn&edition=full","pubTime":"2024-05-18 00:17","pubTimestamp":1715962658,"startTime":"0","endTime":"0","summary":"3月31日，Syndax Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第一财季净利润为-72.40百万美元，同比减少76.03%；其中营业收入为0.00美元，每股基本收益为-0.85美元。机构评级：截至2024年3月31日，当前有12家机构对Syndax Pharmaceuticals, Inc.目标价做出预测，其中目标均价为34.17美元，其中最低目标价为23.00美元，最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180017418b13183b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180017418b13183b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX"],"gpt_icon":0},{"id":"2434016312","title":"Stifel：维持Syndax Pharmaceuticals(SNDX.US)评级，由买入调整至买入评级, 目标价由39.00美元调整至40.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434016312","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2434016312?lang=zh_cn&edition=full","pubTime":"2024-05-09 22:15","pubTimestamp":1715264134,"startTime":"0","endTime":"0","summary":"Stifel：维持Syndax Pharmaceuticals(SNDX.US)评级，由买入调整至买入评级, 目标价由39.00美元调整至40.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050922153587e52a78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050922153587e52a78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SNDX"],"gpt_icon":0},{"id":"2433972145","title":"Syndax Pharmaceuticals, Inc.盘中异动 急速跳水5.00%报22.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433972145","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2433972145?lang=zh_cn&edition=full","pubTime":"2024-05-08 21:34","pubTimestamp":1715175247,"startTime":"0","endTime":"0","summary":"北京时间2024年05月08日21时34分，Syndax Pharmaceuticals, Inc.股票出现异动，股价大幅下挫5.00%。Syndax Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。其相关个股中，Adaptive Biotechnologies Corporation、Repare Therapeutics Inc.、Cel-Sci Corporation涨幅较大，Enveric Biosciences, Inc.、Allarity Therapeutics, Inc.、Clearmind Medicine Inc.较为活跃，换手率分别为201.09%、28.22%、10.98%，振幅较大的相关个股有Y-Mabs Therapeutics, Inc.、Adaptive Biotechnologies Corporation、Veru Inc.，振幅分别为14.76%、13.50%、9.20%。Syndax Pharmaceuticals, Inc.公司简介：Syndax Pharmaceuticals Inc是一家临床阶段的生物制药公司，致力于开发多种癌症适应症的联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082134078ae8de47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082134078ae8de47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2433744442","title":"Syndax Pharmaceuticals(SNDX.US)：2024年Q1财报实现营收0美元，前值为0美元；每股收益为-0.","url":"https://stock-news.laohu8.com/highlight/detail?id=2433744442","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2433744442?lang=zh_cn&edition=full","pubTime":"2024-05-08 19:16","pubTimestamp":1715167006,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","SNDX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":-0.0015},{"period":"1month","weight":-0.1955},{"period":"3month","weight":-0.0163},{"period":"6month","weight":-0.1117},{"period":"1year","weight":0.1089},{"period":"ytd","weight":-0.0764}],"compareEarnings":[{"period":"1week","weight":0.0423},{"period":"1month","weight":-0.0209},{"period":"3month","weight":0.0446},{"period":"6month","weight":0.1072},{"period":"1year","weight":0.258},{"period":"ytd","weight":0.1636}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Syndax Pharmaceuticals, Inc.于2005年10月11日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，正在开发癌症疗法的创新管道。该公司正在开发revumenib，这是一种有效的、选择性的、menin-MLL结合相互作用的小分子抑制剂，用于治疗KMT2A重排或KMT2AR，也称为混合谱系白血病重排或MLLR，包括急性淋巴细胞白血病或ALL在内的急性白血病，以及急性髓细胞白血病或AML，以及necleophosmin 1，也称为NPM1，突变AML。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.044305},{"month":2,"riseRate":0.625,"avgChangeRate":0.07889},{"month":3,"riseRate":0.625,"avgChangeRate":0.084467},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.000613},{"month":5,"riseRate":0.444444,"avgChangeRate":0.006686},{"month":6,"riseRate":0.555556,"avgChangeRate":0.008456},{"month":7,"riseRate":0.555556,"avgChangeRate":0.011483},{"month":8,"riseRate":0.555556,"avgChangeRate":0.043225},{"month":9,"riseRate":0.625,"avgChangeRate":-0.024123},{"month":10,"riseRate":0.25,"avgChangeRate":-0.081003},{"month":11,"riseRate":0.625,"avgChangeRate":0.015744},{"month":12,"riseRate":0.5,"avgChangeRate":0.063584}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals, Inc. ","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Syndax Pharmaceuticals, Inc. ,SNDX,Syndax Pharmaceuticals, Inc. 股票,Syndax Pharmaceuticals, Inc. 股票老虎,Syndax Pharmaceuticals, Inc. 股票老虎国际,Syndax Pharmaceuticals, Inc. 行情,Syndax Pharmaceuticals, Inc. 股票行情,Syndax Pharmaceuticals, Inc. 股价,Syndax Pharmaceuticals, Inc. 股市,Syndax Pharmaceuticals, Inc. 股票价格,Syndax Pharmaceuticals, Inc. 股票交易,Syndax Pharmaceuticals, Inc. 股票购买,Syndax Pharmaceuticals, Inc. 股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals, Inc. (SNDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Syndax Pharmaceuticals, Inc. (SNDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}